Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bénézet, S.
Right arrow Articles by Canal, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bénézet, S.
Right arrow Articles by Canal, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 8:607-609, 1997
© 1997 European Society for Medical Oncology

other

How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients

S. Bénézet1, R. Guimbaud1, E. Chatelut1,2,, E. Chevreau1, R. Bugat1,2 and P. Canal1

1Centre Cloudius Regaud Toulouse, France
2The Universite Paul Sabatier Toulouse, France

Correspondence to: Etienne Chatelut, MD Centre Claudius Regaud 20 rue du Pont St-Pierre F-31052 Toulouse France

BACKGROUND: We previously proposed a formula to predict carboplatin clearance (CL) from four patient characteristics: plasma creatinine level, body weight, age, and sex (J Natl Cancer Inst 1995; 87: 573). Its accuracy was studied in a subpopulation of obese patients.

PATIENTS AND METHODS: Twenty-five patients (16 male and 9 female, 23 to 82 years old) were studied. They were 20% to 67% (median 36%) over the ideal weight which was calculated according to the Lorentz equation. Their actual CL was obtained individually by the Siphar program. The pharmacokinetic population program NONMEM was used to determine the best value of substitution for weight in the formula.

RESULTS: By using the actual weight, CL was significantly overpredicted (by more than 20% for 7 of 25 patients). By using the mean value between the ideal and the actual weight, a good prediction of CL was obtained: the percentage of error ranged from –21% to +22%.

CONCLUSIONS: The formula is applicable to obese patients if both ideal and actual weights are taken into account.

carboplatin, dose adaptation, ideal weight, obesity, pharmacokinetics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
H. Gurney and R. Shaw
Obesity in Dose Calculation: A Mouse or an Elephant?
J. Clin. Oncol., October 20, 2007; 25(30): 4703 - 4704.
[Full Text] [PDF]

Home page
 JCOHome page
A. Sparreboom, A. C. Wolff, R. H.J. Mathijssen, E. Chatelut, E. K. Rowinsky, J. Verweij, and S. D. Baker
Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese
J. Clin. Oncol., October 20, 2007; 25(30): 4707 - 4713.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
V Launay-Vacher, E Chatelut, S. Lichtman, H Wildiers, C Steer, and M Aapro
Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations
Ann. Onc., August 1, 2007; 18(8): 1314 - 1321.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.